3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms by Site
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neoplasms
1
Lung Diseases
1
Head and Neck Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Bronchial Neoplasms
1
Interventions
selpercatinib
2
pralsetinib
2
pembrolizumab
2
Pemetrexed
2
Paclitaxel
2
Carboplatin
2
patritumab
1
osimertinib
1
napabucasin
1
efineptakin alfa
1
durvalumab
1
cobimetinib
1
atezolizumab
1
alectinib
1
Tyrosine Kinase Inhibitors
1
Radiosurgery
1
Proton Therapy
1
Metformin
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Dasatinib
1
Cisplatin
1
Bevacizumab
1
Afatinib
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Thoracic Neoplasms
×
patritumab
×
Clear all
NCT02134015
2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3
Terminated
145 enrolled
20 charts